Non-myeloablative allogeneic stem cell transplantation has been reported to induce sustained complete remission even in advanced diseases (acute leukemia, lymphomas). The tolerance of this procedure allows treatment of poor candidates to conventional allogeneic transplantation with persisting or relapsing myeloma patients. Twelve patients previously treated with at least VAD regimen and autologous transplantation were included. All patients had a serum ␤2 microglobuline Ͼ3 mg/l at diagnosis. The conditioning regimen consisted of fludarabine 25 mg/m/day × 5, antithymoglobulin 2.5 mg/kg/day × 5, busulphan 2 mg/kg/day × 2; the transplant was peripheral stem cells (except one) from an HLA-matched sibling and was followed by cyclosporin for 45 to 90 days. This treatment results in a well-tolerated procedure (no mucositis, duration of aplasia Ͻ7 days). A dramatic graft anti-myeloma effect is documented even in progressive disease (11/12 PR + CR, 4/12 CR). However, five patients underwent CMV disease, one died of CMV encephalitis (UPN 3) and delayed severe GVHD occurred in four patients. Our data suggest that a better survival could be achieved when patients are transplanted with a controlled disease. In high risk patients, we now propose a non-myeloablative transplantation in addition to the conventional and intensive chemotherapy as first-line of treatment. Leukemia (2001) 15, 642-646.
Introduction
Allogeneic bone marrow or peripheral stem cell transplantation has been reported to induce sustained and complete response in multiple myeloma, however only few patients present a long-term, disease-free survival. [1] [2] [3] Relapse rates after allogeneic transplantation for patients alive after 1 year post-transplant are lower than after autologous transplant suggesting an immune control of the disease. 3 The allogeneic control of multiple myeloma (also called graft-versus-myeloma or GVM effect) has been demonstrated by the impact of donor leukocyte infusions as treatment of relapse after allogeneic transplant [4] [5] [6] [7] and may be considered as efficient considering the eight remissions obtained on 13 patients in the study by Lokhorst et al. 8 However, considering the published data on transplantrelated mortality in this disease (41% at 36 months) in the EBMT study reported by Bjorkstrand, 3 allogeneic stem cell transplantation has to be limited to young patients. These data lead to reduced doses in conditioning regimen. 9 Given the results of non-myeloablative allogeneic stem cell transplantation in acute leukemia or lymphoma, where complete remissions were obtained, 10 ,11 a similar approach might benefit myeloma patients. Two types of conditioning regimens has been reported. The first strategy combines the immune effect of the transplant to drugs directed against the disease, this type of combination has been reported as efficient in relapsing acute leukemias or lymphomas. 10, 11 The second type of conditioning regimen focused essentially on immunosuppression only to allow engraftment and allogeneic effect, with the restriction that the data published concerned patients in complete remission or controlled disease. 12 Little is known about allogeneic GVM used alone as salvage therapy in aggressive myeloma patients, and the current published data concern only myeloablative allogeneic transplantation with a high rate of transplant-related mortality and only few patients alive in complete remission. 3, 13 We report here an oligocenter pilot study of non-myeloablative allogeneic stem cell transplantation in high risk patients with relapsing/refractory disease after high-dose therapy and autologous stem cell transplantation.
Patients and methods

Patients
The study was performed in three French Clinical Hematology Departments (Grenoble, Toulouse and Montpellier). Eligible patients were selected on the basis of multiple myeloma with detectable or evolutive (progressive phase of) disease after one line of chemotherapy plus high-dose chemotherapy (two patients had plasma cell leukemia). The objectives of the study were to evaluate the tolerance, early response (at 3 months), and early engraftment.
Selection criteria
Twelve consecutive patients were enrolled. Patients were aged Ͻ65 years, with multiple myeloma with ␤2 microglobulin Ͼ3 mg/l, relapsing or progressive after chemotherapy and autologous transplantation or in refractory/evolutive phase of disease. All patients included were relapsing or progressive within 1 year post-autologous transplantation. Patients were not eligible for conventional allogeneic transplantation (for reasons of age and/or performance status) and had to have an HLA-compatible sibling. Performance status was р2. Characteristics of patients are listed in Table 1 . All patients received at least one conventional chemotherapy line of treatment (VAD regimen) followed by high dose therapy consisting of melphalan 140 mg/m 2 plus total body irradiation (TBI) (8 Gy) or melphalan 200 mg/m 2 alone. In two cases, patients received two sequences of high-dose therapy (melphalan alone and melphalan plus TBI).
The conditioning regimen was modified from Slavin et al, 12 in these high risk, early relapsing or chemoresistant patients, to focus on GVM effect (fludarabine 25 mg/m 2 for 5 days, antithymoglobulins 2.5 mg/kg for 5 days, busulphan 2 mg/kg for 2 days). Prevention of graft-versus-host disease (GVHD) was cyclosporin A (2 mg/kg/day i.v. or 5 mg/kg/day orally) from day −1 for up to 90 days. Corticosteroids (1 mg/kg/day of prednisone) were added from day 7 to day 45 in case of GVHD corticosteroids and or cyclosporin treatment was prolonged. The study was approved by the institutionnal ethic committee, patients and donors gave written informed consent.
Donors and transplants
Transplants were obtained from HLA-matched sibling donors after granulocyte colony-stimulating factor (rhu-G-CSF at 10 g/kg for 4-5 days) treatment and cytapheresis collection of mononuclear cells until a minimum of 2 × 10 6 CD34
+ cell/kg of recipient was obtained. One patient received a marrow transplant. Data concerning the cells infused are given in Table 1 .
Definition of the response
Complete remission (CR) was defined by 5% or less plasmocytes of normal morphology in the bone marrow and absence Leukemia of monoclonal protein on serum electrophoresis and immunofixation analysis, and in cases of Bence Jones proteinuria by its disappearance. Partial response (PR) was defined by a decrease Ͼ50% of the paraprotein in serum or Ͼ90% in urine. Progression was defined by Ͼ25% of paraprotein, relapse (for patients in CR) by reappearance of abnormal plasma cells in marrow or plasmocytoma or reappearance of paraprotein.
Chimerism
Chimerism was studied in bone marrow mononuclear cells by variable number of tandem repeats as previously described 14 and by cytogenetic and FISH analysis in cases of sex mismatch.
Results
Early tolerance
By the choice of peripheral blood stem cell transplants (PBSCT), the tolerance of conditioning was excellent, neutro-penia was delayed (beginning at days 5 to 7 post-transplant) and extremely short (0-11 days); moreover duration was further shortened to 0-3 days by addition of G-CSF. Except in one case, polymorphonuclear counts did not decrease under the level of 0.3 × 10 9 /l allowing the absence of infection during the period of neutropenia. No mucositis was observed, no parenteral feeding was required. Some patients did not require platelet tranfusion (when platelet counts did not decrease below 20 × 10 9 /l). Two patients died early after transplant. Patient No. 6 died from disease progression. This patient received a marrow transplant and despite signs of GVHD, no early GVM occurred. The second patient (No. 4) who died after engraftment had a pre-existing cardiopathy leading to a toxic acute heart failure, however at the time of death, partial response could be documented.
Engraftment and hematological response
Engraftment was detected in all cases and results are shown in Table 2 . Study of the (myeloid + lymphoid) chimerism, when performed, revealed two profiles of transplant installation: in some cases, as occurs in myeloablative transplantation, complete and stable chimerism was detectable following the hematopoietic recovery, and this profile seems to be correlated with a complete response. This was in less than 3 months. The second profile of engrafting was more progressive with recipient cells persisting in the blood or bone marrow at 1 month after transplant. Partial response could be documented at 3 months after transplant. These partial and delayed responses appeared stable. In patient 10, a discordance was observed between a controlled stable disease and complete marrow chimerism (at the molecular level). In cases of progressive disease (after allogeneic transplantation), a logical mixed chimerism was always observed. In patient No. 8, donor leukocyte infusion (DLI) was performed early (at day 60 post-transplant) for no response and absence of signs of acute GVHD; DLI was able to induce a complete remission state, with a leukocyte-induced GVHD. Despite the disease status of the patients before transplant, a strong allogeneic GVM effect could be documented with four complete remissions. Molecular remission was studied in two cases and was also complete (data not shown) and a controlled disease was obtained in most of the other cases (11/12 PR in the first 3 months).
Graft-versus-host disease and other complications
As a supposed consequence of a strong GVM effect, we observed a high incidence of grade III-IV GVHD which required high doses of corticosteroids (leading to death in one case), and often leading to chronic signs of GVHD. Most of the GVHD signs were observed during the first 2 months posttransplant (during the cyclosporin period, except in patient 9 where signs occurred 1 month post-discontinuation of GVHD prevention) and lead to chronic GVHD. Corticosteroid prevention was only administered to patients 1, 2, 6 and 7. In other cases, for reason of progressive disease, we would expect a rapid and strong graft-versus-myeloma effect and corticosteroids were avoided. One patient received DLI and complete remission was achieved with an acute grade III GVHD. One patient died from pneumonia with extensive chronic GVHD after 15 months of survival in transient complete remission and minimal detectable stable disease at the time of death. CMV infection was frequent in this study and five of 11 patients presented signs of infection either systemic (viremia, antigenemia) or localized (colitis, encephalitis). In one case, CMV encephalitis lead to death.
Discussion
Allogeneic transplantation has been reported as a strong treatment for young myeloma patients despite a high transplant mortality with myeloablative conditionning. [1] [2] [3] Benefits in terms of disease-free survival in comparison with high-dose therapy and autologous transplantation were significant only in patients alive after 1 year post-transplant. 3 However, allogeneic GVM effect has been reported as an efficient treatment of relapse after conventional myeloablative allogeneic transplantation. [4] [5] [6] 15 Myeloablative allogeneic transplantation combining a high-dose chemotherapy and GVM effect has also been reported as salvage therapy in some cases of young patients. 16 In this study is presented a salvage therapy based on the only and strong allogeneic GVM effect. Our results (11/12 PR at 3 months) are reinforced by a recent report by Nagler et al, 17 in evolutive or multi-relapsing and resistant lymphomas, demonstrating that a strong anti-lymphoma allogeneic effect did not require an antitumor conditioning. Moreover, the population of patients eligible was restricted to patients with very poor prognosis: evolutive disease before transplant, and previously heavily treated by at least four courses of VAD regimen and one high-dose chemotherapy and autologous transplantation (two patients were treated with a double-autografting sequence). Engraftment occurred with good tolerance and the early period (3 weeks) presented no complications. In our patients engraftment seems to be dissociated from the actual GVM effect, as previously reported in this type of non-myeloablative conditioning. 18 In cases of various malignancies Childs et al 16 reported that allogeneic hematopoietic chimerism occurred progressively and is preceded by T-lymphocyte reconstitution. In our study, graft-versus-malignancy effect occurred early after transplantation and donor hematopoietic engraftment persisted even in the case of relapse or progression after allogeneic transplantation. The GVM effect progressively increased and was completed (when completed) before 3 months. Most patients who were not in complete remission responded to the transplantation with persisting and stable disease (partial response). Despite this, a high mortality was observed (three directly related to a delayed disease progression, two as a consequence of GVHD, one due to CMV infection, two from organ failure). This might be attributed to the status of patients before transplant.
High rates of GVHD in this study could be related to short periods of prophylaxis of the GVHD, occurring after the discontinuation of cyclosporin. Our strategy (early discontinuation of cyclosporin at day 45) was based on the work of Giralt et al 10 in acute leukemia, especially concerning patients with plasma cell leukemia where an early immunological effect was expected to control the disease. With regard to antithymocyte globulins, our doses were reduced compared to Slavin et al, 12 and this could be another element in the occurrence of GVH. Though, in order to improve the GVHD control, prevention with cyclosporin for at least 6 months will be proposed for future patients. Moreover, in allogeneic PBSCT, large amounts of lymphocytes were infused, so in this respect, addition of methotrexate could be debated in advanced stage patients since a strong and early response could be expected. But in situations where myeloma was controlled before graft, a standard GVHD prevention with cyclosporin and methotrexate, or a modification in the doses (or in the origin) of antithymocyte globulins, would be appropriate. Concerning the use of peripheral stem cell transplant, acute GVHD incidence did not differ in peripheral vs marrow transplants in classical Leukemia transplantation unless increase chronic GVHD has been reported. 18 Relapse or myeloma progression after transplantation reveals the variable sensitivity to the allogeneic GVM effect. If most of the patients responded, most of responders had partial responses and the interest of donor leukocytes infusions has to be discussed as maintenance therapy. As previously reported in acute leukemia or in lymphoma, non-myeloablative stem cell transplantation may represent a new strategy for myeloma patients.
Despite the high toxicity, allogeneic transplantation has a place in the treatment of young myeloma patients. Results seem better if allografting is performed early in the disease. 9 Although our results here are limited by the advanced stage of disease at the time of transplantation, non-myeloablative allogeneic stem cell transplantation has a place as treatment of myeloma patients not eligible for myeloablative transplantation. Since high-dose chemotherapy and autologous transplantation have become the standard therapy for myeloma management in patients under 65 years, 13, 19 the present procedure could be proposed as a consolidation treatment after high-dose chemotherapy in very high risk patients (with high levels of ␤2 microglobulin and del 13q).
